GSK develops vaccines and specialty and general medicines, with major areas including infectious diseases, HIV, respiratory and immunology conditions, and oncology. Its portfolio includes shingles and respiratory vaccines as well as medicines sold through ViiV Healthcare, its HIV-focused business. GSK generates revenue from prescription medicines and vaccines supplied through global healthcare systems.
GSK plc ADR (GSK) has a MarketKingdoms composite score of 63.0 (B-), an B-range rating. It ranks 1024th of 1,866 covered companies, 48th of 78 in Healthcare (sector average 64.4) and 7th of 13 in Drug Manufacturers - General. Scores as of 2026-10-26.
Its strongest lenses are Stock selection at 82 (Healthcare average 79) and KPI momentum at 82 (Healthcare average 78). Its weakest lenses are Expansion (growth) at 31 (sector average 50) and Trend (momentum) at 35 (sector average 50).
| Lens | Type | GSK | Healthcare average | Drug Manufacturers - General average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 81 | 81 | 81 | 65th |
| Stock selection | Research signal | 82 | 79 | 78 | 69th |
| KPI momentum | Research signal | 82 | 78 | 77 | 60th |
| Catalyst watch | Research signal | 76 | 74 | 71 | 64th |
| Price (valuation) | Fundamental lens | 81 | 50 | 53 | 94th |
| Expansion (growth) | Fundamental lens | 31 | 50 | 39 | 19th |
| Quality (profitability) | Fundamental lens | 71 | 50 | 60 | 79th |
| Trend (momentum) | Fundamental lens | 35 | 50 | 55 | 28th |
The most recent call analysed was held on 2026-07-28 (fiscal 2026 Q2). After it the composite moved from 81.5 to 80.8. MarketKingdoms checks what management promised on each call against what it later delivered.
The composite at the time of each event; today's composite is 63.0.
The stock's valuation gap is -5.1%: its price is below the path its market, sector and industry moves explain (undervalued versus the model path). Factor sensitivity: market beta 0.77, sector beta 0.26, industry beta 0.71; the factor model explains 59% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Amgen Inc. (AMGN) | 71.9 | B+ | +13.9% |
| Eli Lilly & Co. (LLY) | 71.2 | B+ | +1.7% |
| AbbVie Inc. (ABBV) | 69.0 | B | -3.2% |
| Bristol-Myers Squibb Co. (BMY) | 66.3 | B | -11.0% |
| Biogen Inc. (BIIB) | 65.9 | B | +31.0% |
| Gilead Sciences Inc. (GILD) | 65.5 | B | -3.5% |
| Novo Nordisk ADR (NVO) | 62.9 | B- | -24.0% |
| Novartis AG ADR (NVS) | 62.1 | B- | -3.9% |
GSK plc ADR financial statements · Healthcare sector ranking · Drug Manufacturers - General industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.